676495 VEGF Inhibitor, V1 - Calbiochem

676495
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₄₀H₆₁N₁₁O₉

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      676495-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewAn NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
          Catalogue Number676495
          Brand Family Calbiochem®
          SynonymsATWLPPR
          References
          ReferencesStarzec, A., et al. 2006. Life Sci. 79, 2370.
          Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.
          Product Information
          ATP CompetitiveN
          FormWhite lyophilized solid
          FormulationSupplied as a trifluoroacetate salt.
          Hill FormulaC₄₀H₆₁N₁₁O₉
          Chemical formulaC₄₀H₆₁N₁₁O₉
          Hygroscopic Hygroscopic
          ReversibleN
          Applications
          Biological Information
          Primary TargetSpecifically competes against VEGF165 binding to recombinant NRP-1
          Primary Target IC<sub>50</sub>60 µM for specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableN
          Peptide SequenceH-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          VEGF Inhibitor, V1 - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          VEGF Inhibitor, V1 - Calbiochem Certificates of Analysis

          TitleLot Number
          676495

          References

          Reference overview
          Starzec, A., et al. 2006. Life Sci. 79, 2370.
          Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision10-June-2009 RFH
          SynonymsATWLPPR
          DescriptionAn NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
          FormWhite lyophilized solid
          FormulationSupplied as a trifluoroacetate salt.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₄₀H₆₁N₁₁O₉
          Peptide SequenceH-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
          Purity≥95% by HPLC
          SolubilityDMSO (5 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesStarzec, A., et al. 2006. Life Sci. 79, 2370.
          Binetruy-Tournaire, R., et al. 2000. EMBO J. 19, 1525.